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Although both sodium glucose co-transporter 2 inhibition by dapagliflozin and
thiazolidinedione, pioglitazone have glucose-lowering and anti-inflammatory effects,
the therapeutic efficacy of their combination on diabetic nephropathy has not been
investigated. 9-week-old male db/db mice were randomly assigned to 4 groups and
administrated with (1) vehicle, (2) dapagliflozin, (3) pioglitazone, or (4) dapagliflozin
and pioglitazone combination. Human proximal tubule (HK-2) cells were treated with
glucose or palmitate acid in the presence of medium, dapagliflozin, pioglitazone, or
both. Glomerular tuft area and mesangial expansion of the kidney more reduced in
the combination group compared to control and single therapy groups. Podocyte foot
process width and glomerular basement membrane thickness decreased regardless
of treatment, while the combination group showed the slowest renal hypertrophy
progression (P < 0.05). The combination treatment decreased MCP-1, type I and IV
collagen expression in the renal cortex. Only the combination treatment decreased the
expression of angiotensinogen, IL-6, and TGF-β while it enhanced HK-2 cell survival
(all P < 0.05). In conclusion, dapagliflozin and pioglitazone preserved renal function,
and combination therapy showed the greatest benefit. These findings suggest that the
combination therapy of dapagliflozin with pioglitazone is more effective than the single
therapy for preventing the progression of nephropathy in patients with type 2 diabetes.
Keywords: sodium glucose co-transporter 2 inhibitor, thiazolidinedione, diabetic nephropathy, type 2 diabetes,
db/db mice
INTRODUCTION
Sodium glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the proximal
tubules, and consequently stimulate glucose excretion in the urine (1). Dapagliflozin is a highly
selective and first-in-class SGLT2 inhibitor, which has many favorable effects on glucose lowering
and body weight loss in clinical studies (2, 3). The result of preclinical and animal studies
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demonstrated other beneficial effects of this SGLT2 inhibitor such
as improved glucose homeostasis (4), preserved pancreatic islet
cell function (5, 6), enhanced muscle insulin sensitivity (7), and
attenuated hepatic steatosis (8).
Pioglitazone is in the class of thiazolidinedione (TZD),
which plays essential roles in improving glucose tolerance
and insulin sensitivity (9). Although TZD has a protective
effect against cardiovascular disease and inflammation (10, 11),
this class of drug induces fluid retention and edema, and
aggravates congestive heart failure because of increased sodium
reabsorption (12).
Because of the sodium excreting effect of dapagliflozin, it is
plausible that dapagliflozin can prevent the peripheral edema
that may be induced by pioglitazone treatment. Reducing excess
glucose combined with improving insulin sensitivity could be
an ideal combination for obese patients with type 2 diabetes
(T2D). However, there is limited information on the combination
therapy of SGLT2 inhibitor and TZD in diabetic nephropathy.
We hypothesized that the combination therapy could have a
synergistic effect or at least have an additive effect on preventing
diabetic nephropathy in type 2 diabetes model. Therefore, the
aim of the present study was to investigate the therapeutic
effect of combination therapy in an animal model to support
the experimental rationale for the combination therapy of
pioglitazone and dapagliflozin.
MATERIALS AND METHODS
Animals and Study Design
Eight-week-old male db/db mice were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). After 1 week of
acclimatization, mice were divided into four groups: (1) vehicle
control (phosphate-buffered saline [PBS; Amresco, Solon, OH,
USA] solution) (n = 5), (2) 30mg/kg/day pioglitazone (n = 8),
(3) 2mg/kg/day dapagliflozin (n = 8), or (4) a combination
of 2mg/kg/day dapagliflozin plus 30mg/kg/day pioglitazone
(n= 7). Vehicle or drugs were administrated daily by oral gavage
for 9 weeks. All animal studies were approved by the Animal
Care and Use Committee of the Yonsei University College of
Medicine.
Biochemical Measurements
Blood samples for random glucose measurements were obtained
via tail tip vein and glucose concentrations were determined with
a glucose analyzer (AGM-4100; Allmedicus, Anyang, Korea). On
week 8, spot urine was obtained as previously explained (13), and
stored at −80◦C for analysis. Urinary creatinine was determined
using an autoanalyzer (Molecular Devices, Sunnyvale, CA, USA)
and urinary albumin concentrations were measured using a
commercially available enzyme-linked immunosorbent assay
(ELISA) kit (Abcam, Cambridge, Cambridge, UK) according
to the manufacturer’s protocol. At week 9, an oral glucose
tolerance test was performed following a 6-h fast (14), and blood
samples were taken via tail prior to (0min) and following an
oral glucose bolus (1 g/kg) at 30, 60, 90, and 120min to measure
plasma glucose concentration. At the end of treatment, general
anesthesia was induced via inhalation of 5% isoflurane. Blood
samples were obtained by left ventricular puncture and stored
at −70◦C for subsequent analyses, were centrifuged at 5,000
× g for 15min at 4◦C. Plasma concentrations of triglycerides
(TG; BioVision, Milpitas, CA, USA) and free fatty acid (FFA;
BioAssay Systems, Hayward, CA, USA) were measured using a
colorimetric method according to the manufacturer’s protocols.
Analysis of blood urea nitrogen (BUN) concentration was
performed in the Eone Reference Laboratory (http://www.
eonelab.co.kr, Republic of Korea).
Tissue Collection and Histological Analysis
Paraffin-embedded kidney tissues were cut into 4µm thick
sections and stained with Hematoxylin and Eosin (H&E),
Periodic Acid-Schiff (PAS), and Masson’s trichrome stain. All
tissue sections were examined using a BX40 microscope (OL-
BX40, Olympus, Tokyo, Japan). Mesangial expansion and
glomerular hypertrophy were assessed in a minimum of 15
glomeruli per mouse kidney. The tissue sections were magnified
at×400 and the diameter of the glomerular tuft and PAS-positive
areas were quantified from the glomerulus cut in a plane along
the vascular pole. For transmission electronmicroscopic analysis,
kidney cortical samples were fixed with a solution containing
3% glutaraldehyde plus 2% paraformaldehyde in 0.1 mol/L
phosphate buffer (pH 7.4), followed by 1% osmium tetroxide.
After dehydration, thin sections were stained with uranyl acetate
and lead citrate for observation under a JEM 1011CX electron
microscope (JEOL, USA, Inc.). Histological images were analyzed
using ImageJ software (NIH Image, Bethesda, MD, USA) for
quantifying mesangial expansion and glomerular hypertrophy.
In Situ Cell Death Detection
To investigate the cell death of kidney tubule, Terminal
deoxynucleotidyl transferase (TdT)-mediated digoxigenin-dUTP
nick end labeling (TUNEL) was performed on fixed tissue
sections using a commercially available kit (TACS R© 2TdT
DAB kit, Trevigen, Gaithersburg, MD, USA) according to the
manufacturer’s instructions. Twenty randomly selected areas per
mouse kidney were evaluated under high power magnification
(×400).
Real-Time PCR
The kidney RNA was prepared using Trizol reagent (Thermo
Fisher, Grand Island, NY, USA) according to the manufacturer’s
instructions. Reverse transcription was performed using the
high capacity complementary DNA transcription kit (Applied
Biosystems, Foster City, CA, USA) by real time polymerase chain
reaction (RT-PCR) using the SYBR Green Master Mix (Thermo
Fisher, Grand Island, NY, USA). Expression of transforming
growth factor (TGF)-β, monocyte chemoattractant protein
(MCP)-1, type I and type IV collagens, renin, interleukin (IL)-
6, and angiotensinogen (AGT) was normalized to the reference
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Supplementary Table 1).
Cell Culture
An immortalized human proximal tubule epithelial cell,
HK-2 was maintained in Dulbeco’s Modified Eagle’s Media
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(DMEM) containing 25mM D-glucose supplemented with 10%
fetal bovine serum, penicillin (100U/mL), and streptomycin
(100µg/mL) (Thermo Fisher, Grand Island, NY, USA) (15).
When cell confluency reached to 80% confluence, cells were
exposed to (1) 5.5mM glucose, (2) 50mM glucose, (3) 50mM
glucose plus 0.3mM palmitic acid (Sigma-Aldrich, Saint Louis,
MO, USA), (4) 10µM pioglitazone plus (3) medium, (5) 10µM
dapagliflozin plus (3) medium, or (6) 10µM pioglitazone and
10µM dapagliflozin co-treatment in (3) medium, for 24 h then
harvested (n= 5).
Cell Viability Assay
It was reported that palmitic acid can induce cell death in
HK-2 cells (16–19). To test the effect of dapagliflozin and
pioglitazone on palmitic acid and high glucose induced HK-
2 cell death, Cell viability was measured by the MTT (3-(4-
5-Dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay.
HK-2 cells were seeded into in 96-well plates and incubated
overnight to allow the cells to adhere and, were exposed to same
manner to the condition used for cell culture study [(1) 5.5mM
glucose, (2) 50mM glucose, (3) 50mM glucose plus 0.3mM
palmitic acid, (4) 10µMpioglitazone plus (3)medium, (5) 10µM
dapagliflozin plus (3) medium, or (6) 10µM pioglitazone and
10µM dapagliflozin co-treatment in (3) medium]. At the end
of exposure, 40 µMl of MTT solution (2 mg/ml) was added and
the cells were then incubated withWST-8 (Dojindo Laboratories,
Kumamoto, Kumamoto, Japan) solution at 37◦C for 1 h. Cells
were solubilized with 150 µl of DMSO and absorbance was
quantified in 450 nm using amicroplate reader (VersaMax ELISA
Microplate Reader, Molecular Devices, Sunnyvale, CA, USA).
The cell viability index was calculated as the percentage of control
group which was assumed to be 100%.
Western Blot
Membrane and cytoplasmic proteins were extracted from
cultured HK-2 cell using the Mem-PER Plus Membrane
Protein Extraction Kit (Pierce Biotechnology, Rockford, IL,
USA) and measured suing the bicinchoninic acid assay (Pierce
Biotechnology) according to the manufacturer’s instructions.
Equal amounts of protein (30 µg/well) were resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and analyzed
by western blot using specific antibodies against SGLT2 (cat.
#37296, Abcam, Bristol, UK) and β-Actin (cat. #47778, Santa
Cruz, Dallas, TX, USA). For analysis of the western blot images
were analyzed using ImageJ software (NIH Image, Bethesda,
MD, USA) for quantifying mesangial expansion and glomerular
hypertrophy.
Statistical Analyses
Data were expressed as the mean ± standard error of mean
(SEM). All statistical analyses were conducted using IBM SPSS
version 23.0 for Windows (IBM Corp., Armonk, NY, USA).
Statistical comparisons between groups for body weight and
random blood glucose were performed using two-way analysis
of variance (ANOVA) for repeated measurements (RM) followed
by Tukey’s post-hoc test. For the oral glucose tolerance test,
area under curve (AUC) was calculated and analyzed by 2-way
ANOVA. For the data from the experiments with HK-2 cell,
one-way ANOVA was followed by the Dunnett post-hoc test. For
other comparisons between groups were performed using one-
way ANOVA, followed by the Tukey’s post-hoc test; P < 0.05 was
considered statistically significant.
RESULTS
Physical and Biochemical Characteristics
of db/db Mice
The body weights of all mice gradually increased during the
study period, and the pioglitazone group had significantly
greater weight than the other groups beginning at the 4th
week of treatment (Figure 1A). The P value for interaction
on body weight was 0.041, and dapagliflozin monotherapy
treated mice weighed less than vehicle treated group
(P = 0.036 overall independent of time). The amount of
food consumption was not significantly different between
the groups (P = 0.994). The combination treatment group
experienced the greatest efficacy with 95.3% reduction from
baseline (P = 0.002 compared to vehicle) (Figure 1B) (P
interaction <0.001), and showed the most reduced AUC
(Supplementary Figures 1A,B) (P interaction = 0.032).
Similarly, plasma TG and FFA concentrations were decreased
in treatment groups compared to vehicle-treated mice
(Supplementary Figures 2A,B). The concentration of BUN
was similar across the groups (P interaction = 0.846). In
conclusion, combination treated group showed the greatest
glucose reduction with insignificant difference in body
weight and lipid concentration compared to monotherapy
groups.
Renal Morphology and Albuminuria
Compared to the vehicle-treated group, kidney weights were
lowest in the combination group (Figure 1C). Urine albumin
to creatinine ratio (UACR) was reduced in all treatment arms,
however, no significant difference in UACR was observed
between the treatment groups (Figure 1D).
In immunohistochemistry studies, increased glomerulus size
and tubuloglomerular fibrosis were observed in vehicle mice,
which were attenuated in the treatment groups (Figures 2A–D).
Pioglitazone and dapagliflozin monotherapy groups showed
attenuated glomerular hypertrophy, and both monotherapy
groups showed comparable glomerular tuft size (2971.1 ±
62.0 µm2 for pioglitazone and 2945.2 ± 84.7 µm2 for
dapagliflozin) (Figure 2E). The combination therapy group
showed the greatest reduction in glomerular tuft area (26.4%
reduction compared to vehicle, P < 0.001). Similarly, the
mesangial expansion ratio was lower in the treatment groups,
and was lowest in the combination arm (30.0% reduction
compared to vehicle, P < 0.001) (Figure 2F). Along with these
morphologic changes, TUNEL staining demonstrated more cell
death in the kidney of vehicle mice, which was lower in the
pioglitazone and dapagliflozin groups (Figures 2D,G). With
respect to the three treatment arms, mice treated with the
combination showed the lowest number of apoptotic cells in the
kidney.
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FIGURE 1 | Effects of pioglitazone, dapagliflozin and combination on body
weight, blood glucose, kidney weight, and albuminuria. Graph depicting (A)
body weight and (B) random blood glucose concentration in vehicle (black
square, ), pioglitazone (30mg/kg/day, white circle, ◦), dapagliflozin
(1mg/kg/day,white square ), and combination (30mg/kg/day of pioglitazone
and 1mg/kg/day of dapagliflozin, black circle, •) during 9 week of study
period. (C) Measurement of both kidney weight after 9 weeks treatment in
vehicle (PBS), pioglitazone (30mg/kg/day), dapagliflozin (1mg/kg/day), and
combination (30mg/kg/day of pioglitazone and 1mg/kg/day of dapagliflozin).
(D) Measurements of urine albumin to creatinine ratio after 8 weeks treatment
in vehicle (PBS), pioglitazone (30mg/kg/day), dapagliflozin (1mg/kg/day), and
combination (30mg/kg/day of pioglitazone and 1mg/kg/day of dapagliflozin).
Data are means ± SEM (vehicle n = 5, monotherapy n = 8, combination
therapy n = 7). *P < 0.05 vs. vehicle by one-way ANOVA and Tukey’s
post-hoc test.
Electron microscopic examination showed increased
irregular thickening of the glomerular basement membrane
(GBM) and foot process effacements on glomeruli in the
vehicle mice (Figure 3A). These morphologic changes
were attenuated in all treatment groups (Figures 3B–D).
Podocyte foot process width was reduced by 45.7 and 44.9%,
and GBM thickness was decreased by 37.8 and 37.7% for
the pioglitazone and dapagliflozin monotherapy groups,
respectively (all P < 0.001 compared to vehicle). The
combination-treated group showed the best preservation
of glomerular morphology with 56.6% reduction in
podocyte foot process width and 48.3% reduction in GBM
thickness compared to vehicle. In addition, compared to the
monotherapy groups, combination treatment resulted in better
glomerular structures (GBM thickness P = 0.038 compared
to pioglitazone, P = 0.020 compared to dapagliflozin; foot
process width P = 0.033 compared to pioglitazone, P = 0.027
compared to dapagliflozin) (Figure 4A,B). In conclusion,
combination treated group showed the greatest preserved renal
morphology change compared to monotherapy and vehicle
groups.
Inflammatory, Profibrotic, and
Renin-Angiotensin System-Related Gene
Expression
Decreased trends in inflammatory gene expression were observed
in the three treatment groups. TGF-β mRNA level was
significantly decreased only in the combination-treated mice
(Figure 5A). Regarding MCP-1, all treatment groups had
decreased expression compared to vehicle; however, there was
no significant differences between the groups (Figure 5B). The
fibrosis markers, type I and type IV collagen, were decreased
in the pioglitazone monotherapy and combination groups
(Figure 5C,D) (all P < 0.05).
The renal renin-angiotensin system (RAS) activity
tended to decrease in the treatment groups (Figure 6).
Dapagliflozin and pioglitazone-treated mice showed lower
AGT expression compared to vehicle-treated mice; however,
only the combination group had reduced AGT expression
(P = 0.008). In conclusion, the combination treated group
showed the greatest reduction in renal markers of inflammation
and fibrosis compared to both the monotherapy and vehicle
groups.
Effect of Dapagliflozin and Pioglitazone
Treatments on HK-2 Cells
As vehicle db/db mice showed increased blood glucose and lipid
concentrations compared to treated mice, we evaluated high
glucose and high lipid-induced inflammation and RAS activation
and the direct renoprotective effect of dapagliflozin, pioglitazone,
and combination therapy in in vitro studies. Compared to
cells in normal glucose, the TGF-β/GAPDH mRNA ratios were
6-fold higher in tubular cells exposed to high glucose and
palmitate medium (P < 0.05) (Supplementary Figure 3A). This
increase in TGF-β mRNA expression was attenuated by single
or combination treatment (all P < 0.05). The levels MCP-
1 protein in conditioned culture medium showed a similar
pattern to the TGF-β mRNA expression (Supplementary Figure
3B). The level of IL-6 protein was significantly decreased only
in the combination-treated mice (Supplementary Figure 3C).
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FIGURE 2 | Effects of pioglitazone, dapagliflozin and combination on kidney morphology in immunohistochemistry studies. Renal glomerulus and tubules of 9 weeks
treatment in vehicle (PBS), pioglitazone (30mg/kg/day), dapagliflozin (1mg/kg/day), and combination (30mg/kg/day of pioglitazone and 1mg/kg/day of dapagliflozin).
(A) Hematoxylin and Eosin (H&E) stain, (B) Periodic acid-Schiff (PAS) stain, (C) Masson’s trichrome stain, (D) Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) stain (×400, bar presents 200µm). Quantification of (E) glomerular tuft area, and (F) mesangial expansion in PAS stain section minimum of 15
glomeruli per mouse kidney under high power magnification (×400). (G) Counting apoptotic tubular cell in TUNEL stain minimum of 20 randomly selected areas per
mouse kidney under high power magnification (×400). Data are means ± SEM (vehicle n = 5, monotherapy n = 8, combination therapy n = 7). **P < 0.001 vs. vehicle,
†P < 0.05 vs. pioglitazone, ††P < 0.001 vs. pioglitazone, §P < 0.05 vs. dapagliflozin, §§P < 0.001 vs. dapagliflozin by one-way ANOVA and Tukey’s post hoc test.
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FIGURE 3 | Effects of pioglitazone, dapagliflozin and combination on glomerulus morphology by electron microscope. Glomerulus of 9 weeks treatment in vehicle
(PBS, A), pioglitazone (30mg/kg/day, B), dapagliflozin (1mg/kg/day, C), and combination (30mg/kg/day of pioglitazone and 1mg/kg/day of dapagliflozin, D).
Glomerulus of each treated group ×30,000 magnification.
FIGURE 4 | Effects of pioglitazone, dapagliflozin and combination on glomerulus foot process and basement membrane. Quantification of (A) foot process width, and
(B) glomerular basement membrane thickness under high power magnification (×30,000). Data are means ± SEM (n = 5–8). **P < 0.001 vs. vehicle, †P < 0.05 vs.
pioglitazone, §P < 0.05 vs. dapagliflozin by one-way ANOVA and Tukey’s post-hoc test.
The renin expression was not significantly different across
the groups (Supplementary Figure 3D). However, the increase
in AGT was significantly attenuated with all treated mice
group (Supplementary Figure 3E). Supplementary Figure 3F
depicts the trend that showed cell survival recovery in the
treatment groups; monotherapy and combination treatment had
statistically significant recovery. Moreover, the concentration
of SGLT2 protein in the HK-2 membrane fraction was not
different between the groups (Supplementary Figure 4; P= 0.002
for pioglitazone, P = 0.001 for combination). In conclusion,
combination treated group showed the greatest reduction
in IL-6 expression with insignificant difference in MCP-1,
TGF-β, AGT, and cell recovery compared to monotherapy
groups.
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FIGURE 5 | Comparison of inflammatory and profibrotic gene expression in mouse renal cortex. Real-time PCR for 9-week vehicle (PBS)-, pioglitazone
(30mg/kg/day)-, dapagliflozin (1mg/kg/day)-, and combination (30mg/kg/day of pioglitazone and 1mg/kg/day of dapagliflozin)-treated mice’ renal cortex. (A) TGF-β
(encoding transforming growth factor β), (B) MCP-1 (encoding monocyte chemoattractant protein-1), (C) type 1 collagen, (D) type IV collagen. Data are means ±
SEM (vehicle n = 5, monotherapy n = 8, combination therapy n = 7). *P < 0.05 vs. vehicle by one-way ANOVA and Tukey’s post-hoc test.
FIGURE 6 | Comparison of angiotensinogen expression in mouse renal cortex.
Real-time PCR for 9-week vehicle (PBS)-, pioglitazone (30mg/kg/day)-,
dapagliflozin (1mg/kg/day)-, and combination (30mg/kg/day of pioglitazone
and 1mg/kg/day of dapagliflozin)-treated mice’ renal cortex. Data are means
± SEM (vehicle n = 5, monotherapy n = 8, combination therapy n = 7).
*P < 0.05 vs. vehicle by one-way ANOVA and Tukey’s post-hoc test.
DISCUSSION
In the present study, we tested the hypothesis that dapagliflozin
and pioglitazone combination therapy would prevent
T2D-related renal injury and examined its effects on metabolic
parameters in a db/db mouse model. The results showed that
pathological changes in renal cortex, increased albuminuria,
and upregulated expression of fibrotic and RAS-related genes in
the kidney were ameliorated in the dapagliflozin, pioglitazone,
and combination treatment groups. Furthermore, the most
attenuation of glomerular hypertrophy, amelioration of fibrosis,
and AGT gene expression was observed in the combination
group. We also demonstrated that dapagliflozin, pioglitazone,
and combination therapy resulted in reduced inflammatory and
RAS-related gene expression in the HK-2 cell experiments.
Classically, the anti-inflammatory mechanism of TZD on
diabetic nephropathy has been well established (20–22). An
in vitro study of mesangial cells, pioglitazone attenuated
high glucose-induced MCP-1 synthesis, NF-kB activation, and
collagen synthesis (23). In addition, increased antioxidant
enzyme induction (Cu-Zn SOD, GSH-Px) in the kidney was
ameliorated in a TZD-treated type 1 diabetes animal model,
without the glucose-lowering effect, which suggested that TZD
has an independent renoprotective effect based on reactive
oxygen species inhibition (24). In our study, upregulated
expression of TGF-β, type I and type IV collagens was
ameliorated in the pioglitazone monotherapy group. Along with
TZD, recent studies support the evidence that SGLT2 inhibitors
have a beneficial effect on diabetic nephropathy. SGLT2 in the
proximal tubules reabsorb the majority of glucose in the kidney;
thus, inhibition of SGLT2 can lower glucose concentration as
well as diabetes-related complications (25, 26). In a 12-week
study, dapagliflozin fed to male db/dbmice resulted in decreased
macrophage infiltration by improvement of hyperglycemia in a
dose-dependent manner (27). Similarly, treatment of db/dbmice
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with another SGLT2 inhibitor, empagliflozin, resulted in reduced
molecular and histological markers of kidney fibrosis and
tubule damage (kidney injury molecule-1, neutrophil gelatinase-
associated lipocalin) when administered with metformin or
linagliptin (28, 29). SGLT2 inhibitor treatment in HK-2 cells
reversed high glucose-induced inflammatory marker expression
(toll-like receptor 4, NF-kB) (30). Furthermore, the EMPA-REG
trial outcome provided clinical evidence that SGLT2 inhibitors
reduce nephropathy incidence or progression (31). Tofogliflozin
has also been investigated for preventing progression of diabetic
nephropathy (32).
However, it seems that dapagliflozin and pioglitazone
combination therapy involves other renoprotective mechanisms
beyond glucose-lowering effects. Based on our study, although
blood glucose levels were lowest in the combination group
at the end of treatment, there was no statistically significant
difference in blood glucose or oral glucose tolerance test between
the three treatment arms. Kidney weights and morphologic
changes were mostly improved in the combination group. In
addition, only the combination therapy showed significantly
reduced TGF-β and AGTmRNA expression. Hyperglycemia and
dyslipidemia contribute to renal injury via increased oxidative
stress and impaired sodium handling (33, 34). At the early
onset of diabetic nephropathy, sodium reabsorption in proximal
tubules is upregulated, and activated tubuloglomerular feedback
increases the single nephron glomerular filtration rate, referred
as hyperfiltration (35). As diabetic nephropathy progresses, GBM
thickening, mesangial matrix expansion, extracellular matrix
accumulation, and tubulointerstitial fibrosis appear. The increase
in proximal tubular reabsorption results in tubular hypertrophy
and the structural change is mediated by inflammation and
growth factors, mainly TGF-β (36). Along with TGF-β activation,
upregulated RAS-related components (renin and angiotensin II)
bind to vascular endothelial growth factor and induce renal
cell growth and extracellular matrix synthesis (37). The RAS
involvement in stimulatingmorphogenesis in renal cells is mainly
mediated through angiotensin II type 1 receptor (38). Moreover,
angiotensin II mediates transcription of the TGF-β receptor gene,
directly upregulating TGF-β or indirectly stimulating MCP-1
(38). The renal RAS pathway also is involved in cardiovascular
disease (39), which is reflected in the cardiovascular benefit of
SGLT2 inhibitors (31).
Although we demonstrated the improvement on renal
morphology and renin and angiotensin gene expressions in
combination therapy, we could not find any additive effect
on blood glucose level. Interestingly, the body weights of
the combination group were more similar to those of the
dapagliflozin group than the pioglitazone group. Considering the
small dose of dapagliflozin, the body weight differences between
the intervention groups could be meaningful. In addition, our
results showed that a small dose of dapagliflozin had equivalent
efficacy to pioglitazone on glucose lowering and nephropathy
prevention.
The current study provides in vivo and in vitro evidences that
dapagliflozin, pioglitazone, and combination therapy attenuated
diabetic nephropathy including albuminuria, renal hypertrophy,
and inflammatory and fibrotic markers. In addition, this
investigation demonstrated decreased renal expression of RAS
components in treated mice. To our knowledge, the current
study is the first to compare the renoprotective effect of SGLT2
inhibitor combination therapy to pioglitazone. Although we
did not elucidate the synergistic mechanism of combination
therapy, we observed a tendency toward lower profibrotic and
inflammatory gene expression in the combination therapy group,
which might have been due to the additive effect of those two
medications. With respect to body weight, the combination
therapy would be expected to provide complementary
effects.
In conclusion, the current study showed that dapagliflozin,
pioglitazone, and combination therapy significantly attenuated
diabetic nephropathy progression, and that the renoprotective
effect was magnified by combination treatment. Therefore,
dapagliflozin and pioglitazone combination therapy could be an
effective option to prevent diabetic nephropathy.
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